Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31425070 | 1.00 | MAPK14 (0.44) | MAPK14NPC1RAB9ACCR5SLC6A4 | |
| SCHEMBL23273445 | 0.83 | HPD (0.43) | MAPK14NPC1RAB9ACCR5PTGER1 | |
| SCHEMBL29737930 | 0.83 | HPD (0.43) | MAPK14NPC1RAB9ACCR5PTGER1 | |
| SCHEMBL29825377 | 0.81 | MAPK14 (0.47) | MAPK14PRMT5EGFRPTGER1 | |
| SCHEMBL23286936 | 0.81 | MAPK14 (0.47) | MAPK14PRMT5EGFRPTGER1 | |
| SCHEMBL24320312 | 0.80 | PTGER1 (0.48) | MAPK14CCR5PTGER1 | |
| SCHEMBL29664227 | 0.80 | MAOB (0.50) | MAPK14NPC1RAB9A | |
| SCHEMBL23362070 | 0.80 | MAOB (0.50) | MAPK14NPC1RAB9A | |
| SCHEMBL23286738 | 0.78 | NPC1 (0.40) | MAPK14NPC1RAB9APRMT5EGFR | |
| SCHEMBL23286794 | 0.78 | MAOB (0.40) | MAPK14NPC1RAB9APRMT5EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPK14 2254/4885NPC1 1188/4885RAB9A 478/4885 |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MAPK14 2254/4885NPC1 1188/4885RAB9A 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.